Mumbai, Nov. 18 -- The agreement aims to accelerate access to SZC, an innovative treatment for hyperkalaemia, across the country.

Hyperkalaemia, a clinically significant condition, disproportionately affects patients with chronic kidney disease (CKD) and heart failure (HF) receiving RAAS inhibitor therapy, which can elevate serum potassium levels. Studies indicate that the condition occurs in up to 50% of CKD patients and 42% of chronic HF patients.

Under the pact, both companies will promote, market, and distribute SZC under different brand names-AstraZeneca as Lokelma and Sun Pharma as Gimliand. AstraZeneca will retain intellectual property rights, marketing authorization, and the import license for the therapy.

This partnership mark...